Antibody-based therapeutics

#Antibody discovery workflow #Antibody-based therapeutics #Biologics #Monoclonal antibodies

Biologics developability: How Merck creates developability profiles for their mAbs

In this Application Note, discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they… Read More

#Resources

Immunotherapy
#Antibody-based therapeutics #Cancer research #Immunotherapy #Oncology #T cell activation

Targeting advances in immunotherapies

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Christian Leisner, Chief Executive Officer of antibody therapeutics' developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Why are existing immunotherapies restricted to certain patient populations?  CL: Immunotherapies, principally anti-PD-1/-L1 checkpoint inhibitors,… Read More

#Cancer Research #Exclusive Content

Antibodies
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Start-ups

Advancing antibody discovery with AI

Listen to this article on the DDW Podcast: DenovAI is the second start-up to launch from the global pharma consortium AION Labs -  an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. DDW Editor Reece Armstrong, speaks to Kashif… Read More

#Exclusive Content #Start-up Zone

Biomarkers concept
#Antibody-based therapeutics #Biomarkers #Cancer research #DDW Turning Science into Business Summit #Oncology

DDW Cancer Summit: Master biomarker-driven approaches

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET and will be available on-demand after that date. The free… Read More

#News

#Antibody-based therapeutics #Artificial intelligence (AI) #CAR-T #Mergers and acquisitions #Microbiome #Partnership #Proteomics

Drug discovery deals highlight key growth areas

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire proteomics company Olink in… Read More

#Business & Investment #News

DDW Antibodies eBook
#Antibodies #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Drug development #Drug discovery

Antibody discovery: Breakthroughs accelerating therapeutic antibodies

This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends in the antibody-drug conjugate (ADC) market… Read More

#DDW eBooks #Intelligence

Antibodies
#Antibody-based therapeutics #Cancer research #Cancer Research Horizons #Oncology #Synthetic libraries #Twist Bioscience

Partnership could enhance antibody discovery for cancer research

Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, a collection of synthesised antibody libraries designed based on naturally occurring sequences that… Read More

#Cancer Research #News

#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

The future of antibody based drugs: Where are the opportunities?

This report will:   Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future  Explore what’s next for antibody-based drugs and where the opportunity is coming from  Include an interview Bio-Rad’s… Read More

#DDW eBooks #Intelligence

Antibodies
#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

DDW In Focus e-report on the future of antibody-based drugs

Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here.  This report will:   Provide an overview of the monoclonal… Read More

#News

#Antibody #Antibody-based therapeutics #Biotechnology #Drug development #Drug discovery #Genomics #Single-cell analysis

Using single-cell technology to create human antibody-based therapeutics

San Francisco-based biotechnology company Infinimmune is emerging from stealth with its $12 million seed financing. The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human… Read More

#Business & Investment #Exclusive Content

Research scientists in laboratory
#Abbie #Antibodies #Antibody-based therapeutics #Cancer research #Collaboration #Immunome #Oncology #Partnership

Collaboration to identify up to 10 novel target-antibody pairs

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.  Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More

#Business & Investment #Cancer Research #News

#Antibodies #Antibody #Antibody discovery workflow #Antibody-based therapeutics #Bethyl Laboratories #Drug discovery

Why choose Bethyl antibodies for your R&D

This article is sponsored by Bethyl Laboratories. For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. We are vertically-integrated from immunisation through manufacturing and validation. All of our antibodies are… Read More

#News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

eBook cover
#Antibody-based therapeutics #Drug development #Monoclonal antibodies

Efficiently develop antibody-based therapeutics

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#Resources

Antibodies
#Antibody #Antibody-based therapeutics #eBook #Monoclonal antibodies #Stability characterisation

New eBook: Efficiently develop antibody-based therapeutics 

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#News